Menopausal Hormone Therapy

摘要: Abstract Background: Although estrogen has been clinically available for more than 6 decades, women have confused by different opinions regarding the risks and benefits of menopausal hormone therapy (HT), (ET), estrogen-progestin (EPT). The publication recent randomized controlled trials (RCTs), notably, Heart Estrogen Replacement Study (HERS), Women's Health Initiative (WHI), Memory (WHIMS), intensified risk versus benefit controversy prompted this review. Objective: We provide a systematic, comprehensive, critical review selected literature that addresses basic clinical aspects HT. Results: Solid, consistent evidence based on observational, epidemiologic, underpins efficacy HT its regulatory agency-approved indications: vasomotor symptoms, vulvovaginal atrophy osteoporosis-related fracture prevention. ET EPT increase venous thromboembolism, although absolute number events are both small. Though there is small in breast cancers who used 10 years, biological meaning observation (cause unmasking chance) unresolved. Most shows does not affect cancer recurrence overall longevity higher survivors select Strong science observational show cardiovascular central nervous systems. Data from RCTs included predominantly overweight aged between 63 71 years reported to harm benefit; rush generalize these studies all regimens unjustified. Conclusion: Menopausal improves symptoms prevents fracture. increases likelihood but other harms such as require further studies. A or system disease prevention unproven. newly women, less 3 menopause, urgently needed investigate aging diseases.